Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Bedaquiline: Current Status and Future Perspectives Publisher Pubmed



Khoshnood S1 ; Goudarzi M2 ; Taki E3 ; Darbandi A4 ; Kouhsari E5 ; Heidary M6, 7 ; Motahar M8 ; Moradi M8 ; Bazyar H9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical MicrobiologyResearch Center, Ilam University of Medical Sciences, Ilam, Iran
  2. 2. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
  6. 6. Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
  7. 7. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
  8. 8. Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  9. 9. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Source: Journal of Global Antimicrobial Resistance Published:2021


Abstract

The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent. © 2021 The Author(s)
Related Docs
1. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis, Frontiers in Microbiology (2021)
2. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria, Frontiers in Microbiology (2017)
3. Scrutinizing the Drug Resistance Mechanism of Multi- and Extensively-Drug Resistant Mycobacterium Tuberculosis: Mutations Versus Efflux Pumps, Antimicrobial Resistance and Infection Control (2019)
4. Whole Genome Sequencing Results Associated With Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs Among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis From Iran, Journal of Clinical Medicine (2020)
5. Molecular Detection of Rifampin, Isoniazid, and Ofloxacin Resistance in Iranian Isolates of Mycobacterium Tuberculosis by High-Resolution Melting Analysis, Infection and Drug Resistance (2018)
6. National Treatment Outcome and Predictors of Death and Treatment Failure in Multidrug-Resistant Tuberculosis in Ethiopia: A 10-Year Retrospective Cohort Study, BMJ Open (2021)
7. Intermittent Treatment Interruption and Its Effect on Multidrug Resistant Tuberculosis Treatment Outcome in Ethiopia, Scientific Reports (2019)
Experts (# of related papers)
View all Related Experts
Mehdi Yaseri (3)
Mohammad Mehdi Feizabadi (2)